Consynance Logo.png

ConSynance will participate in BIO International Convention 2022

May 19, 2022

The upcoming BIO International convention is back in-person for 2022, to be held in San Diego, California from June 13-16. ConSynance are looking forward to four days of networking, programming, and partnering opportunities.

Schedule a One-on-One Partnering™ in-person meeting with ConSynance or contact us here

ConSynance sponsors and will participate in the 11th International Prader-Willi Syndrome Organisation (IPWSO) conference 2022

May 15, 2022

ConSynance is glad to be a sponsor of the 11th IPWSO Conference which is being held in Limerick, Ireland, from July 6 - 10, 2022. CEO Shuang Liu will be attending and presenting a poster at the upcoming conference, titled: CSTI-500 – A Novel Triple Reuptake Inhibitor for the Management of Symptoms Associated with PWS: Delivery via a Unique, Individualized, PK-guided Dosing Approach

 11th IPWSO Conference 2022 - IPWSO

ConSynance sponsors the Prader-Willi Alliance of New York (PWANY) 30th Annual Conference

May 10, 2022

ConSynance is glad to be a sponsor of the PWANY conference, to be held in Binghamton, NY, on May 20 – 21, 2022. ConSynance CEO Shuang Liu will be attending.

Conference Information – Prader-Willi Alliance of New York, Inc.

Partnership with Harmony Biosciences to Develop and Commercialize CSTI-100 (now HBS-102) 

August 9, 2021

We are very excited to announce the signing of a partnership agreement with Harmony Biosciences.  Under the terms of the agreement, Harmony Biosciences will acquire the full development and commercialization rights globally, with the exception of Greater China, of CSTI-100 (now HBS-102), a Melanin Concentrating Hormone Receptor 1 (MCHR1) antagonist.  HBS-102, a potential first-in-class molecule with a novel mechanism of action, has the potential to offer a novel approach to the treatment of narcolepsy including the symptoms of Rapid Eye Movement (REM) sleep dysregulation, such as cataplexy, hallucinations, and sleep paralysis. The financial terms include an upfront payment of $3.5 million and potential development and regulatory milestone payments and royalties. Please also see the press release from Harmony.